Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Consensus Recommendation of “Buy” by Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have been assigned a consensus rating of “Buy” from the eight research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company.

BAYRY has been the topic of several analyst reports. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Friday, July 10th. Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a research note on Friday, May 29th. DZ Bank raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Thursday, July 2nd.

Bayer Aktiengesellschaft Price Performance

BAYRY stock opened at $13.84 on Monday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.70 and a current ratio of 1.05. The firm has a 50 day moving average price of $13.03 and a 200-day moving average price of $12.17. Bayer Aktiengesellschaft has a 52-week low of $7.48 and a 52-week high of $15.23. The firm has a market capitalization of $54.39 billion, a price-to-earnings ratio of -27.14, a PEG ratio of 4.34 and a beta of 0.55.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.06. Bayer Aktiengesellschaft had a positive return on equity of 17.00% and a negative net margin of 3.80%.The company had revenue of $12.53 billion for the quarter, compared to the consensus estimate of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Equities research analysts forecast that Bayer Aktiengesellschaft will post 1.28 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.